LON:GSK GSK (GSK) Share Price, News & Analysis GBX 1,425.50 +10.00 (+0.71%) As of 07:56 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesSustainabilityBuy This Stock About GSK Stock (LON:GSK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GSK alerts:Sign Up Key Stats Today's Range 1,417.50▼ 1,425.5050-Day Range 1,264▼ 1,53652-Week Range 1,242.50▼ 1,808.50Volume39.43 million shsAverage Volume15.89 million shsMarket Capitalization£57.84 billionP/E Ratio23.03Dividend Yield4.21%Price TargetGBX 1,862.50Consensus RatingModerate Buy Company OverviewGSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development, as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.Read More… GSK Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreGSK MarketRank™: GSK scored higher than 72% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingGSK has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 5 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageGSK has only been the subject of 2 research reports in the past 90 days.Read more about GSK's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of GSK is 22.99, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.94.Price to Earnings Ratio vs. SectorThe P/E ratio of GSK is 22.99, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.79.Price to Earnings Growth RatioGSK has a PEG Ratio of 1.24. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGSK has a P/B Ratio of 4.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for GSK. Dividend1.7 / 5Dividend StrengthWeak Dividend LeadershipGSK is a leading dividend payer. It pays a dividend yield of 4.25%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthGSK does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of GSK is 96.92%. Payout ratios above 75% are not desirable because they may not be sustainable.Read more about GSK's dividend. Sustainability and ESG4.4 / 5Environmental Score-1.56 Short InterestThere is no current short interest data available for GSK. News and Social Media2.0 / 5News Sentiment0.61 News SentimentGSK has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for GSK this week, compared to 5 articles on an average week.Search InterestOnly 18 people have searched for GSK on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat Follows2 people have added GSK to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, GSK insiders have sold 860.62% more of their company's stock than they have bought. Specifically, they have bought £8,255.50 in company stock and sold £79,303.77 in company stock.Percentage Held by InsidersOnly 1.61% of the stock of GSK is held by insiders.Percentage Held by Institutions45.33% of the stock of GSK is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GSK's insider trading history. Receive GSK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Email Address GSK Stock News HeadlinesGSK plc (LON:GSK) Insider Julie Brown Acquires 10 SharesMay 14, 2025 | insidertrades.comGSK plc (LON:GSK) Insider Emma Walmsley Sells 5,473 SharesMay 9, 2025 | insidertrades.comGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.May 21, 2025 | Weiss Ratings (Ad)Japan approves GSK’s Blenrep combinations for multiple myeloma treatmentMay 19 at 7:51 AM | in.investing.comGSK plc (LON:GSK) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 19 at 2:51 AM | americanbankingnews.comJulie Brown Purchases 10 Shares of GSK plc (LON:GSK) StockMay 15, 2025 | americanbankingnews.comGSK to buy liver disease drug for up to $2 billionMay 14, 2025 | msn.comWho’s Andrew Witty, the CEO who just stepped down at UnitedHealth?May 13, 2025 | msn.comSee More Headlines GSK Stock Analysis - Frequently Asked Questions How have GSK shares performed this year? GSK's stock was trading at GBX 1,346.50 at the start of the year. Since then, GSK stock has increased by 5.7% and is now trading at GBX 1,423. View the best growth stocks for 2025 here. How were GSK's earnings last quarter? GSK plc (LON:GSK) posted its earnings results on Wednesday, April, 30th. The company reported $44.90 earnings per share (EPS) for the quarter. GSK had a net margin of 8.02% and a trailing twelve-month return on equity of 18.08%. How do I buy shares of GSK? Shares of GSK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of GSK own? Based on aggregate information from My MarketBeat watchlists, some other companies that GSK investors own include AstraZeneca (AZN), Vodafone Group Public (VOD), Lloyds Banking Group (LLOY), Secure Trust Bank (STB), Barclays (BARC), Meta Platforms (META) and Intel (INTC). Company Calendar Last Earnings4/30/2025Today5/21/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - General Sub-IndustryPharmaceutical Products Current SymbolLON:GSK CIKN/A Webwww.gsk.com Phone+44-20-80475000FaxN/AEmployees70,212Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 1,862.50 High Stock Price TargetGBX 2,100 Low Stock Price TargetGBX 1,600 Potential Upside/Downside+30.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 61.91 Trailing P/E Ratio22.99 Forward P/E Ratio8.09 P/E Growth1.24Net Income£2.50 billion Net Margins8.02% Pretax MarginN/A Return on Equity18.08% Return on Assets9.56% Debt Debt-to-Equity Ratio114.64 Current Ratio0.81 Quick Ratio0.73 Sales & Book Value Annual Sales£31.14 billion Price / Sales1.85 Cash FlowGBX 174.70 per share Price / Cash Flow8.15 Book ValueGBX 329.73 per share Price / Book4.32Miscellaneous Outstanding Shares4,057,829,779Free FloatN/AMarket Cap£57.74 billion OptionableNot Optionable Beta0.31 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (LON:GSK) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GSK plc Please log in to your account or sign up in order to add this asset to your watchlist. Share GSK With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.